Diabetes raises fragility fracture risk through bone microarchitecture and through falls, and it does so at bone mineral density values that look reassuring. That combination is what makes it dangerous: the tool most clinics use to decide who needs treatment systematically underestimates risk in exactly this group. A joint consensus from the Taiwanese Association of Diabetes Educators, the Taiwanese Osteoporosis Association and the Endocrine Society of the Republic of China sets out how to handle that.

The recommendations are practical. Screen for osteoporosis early in people with diabetes rather than at the age you would otherwise start. Adjust the risk calculation, because standard calculators underestimate here. Treat non-pharmacological management — exercise, fall prevention, nutrition — as a core component rather than advice appended to a prescription. Anti-osteoporosis drugs work as well in diabetes as outside it, so there is no reason to withhold or downgrade them, and some may improve glycaemic measures. And the glucose-lowering regimen itself has skeletal consequences that belong in the prescribing decision.

This matters disproportionately in India, where type 2 diabetes is common, presents earlier and is frequently managed without any bone assessment at all. A patient in their fifties with fifteen years of diabetes is a fracture-risk patient, and the consensus is an argument for bringing the dual-energy X-ray absorptiometry scan forward rather than waiting for the first fracture to prompt it.

Screen for osteoporosis earlier in diabetes than you would in a comparable person without it.
Treat a reassuring bone mineral density in diabetes with suspicion — fracture risk is raised independently of it.
Assess falls explicitly: neuropathy, visual impairment, hypoglycaemia and postural drop all contribute.
Do not avoid anti-osteoporosis drugs on the grounds of diabetes; efficacy is comparable.
Consider the skeletal effect when choosing or changing glucose-lowering therapy.

Why it matters

The tool most clinics rely on to decide who needs bone protection is the tool that fails in this group.

Don't overread it

This is an expert consensus built from existing guidelines and opinion, not new trial evidence, and it was written for Taiwanese practice — the screening thresholds are not automatically Indian ones.